Situation: A large European pharmaceutical company was increasingly losing revenues from products facing generic competition.
CRA contribution: After an initial diagnostic phase, CRA identified internal inefficiencies in the international tendering process as a major driver of these losses. Working closely with country organizations, we developed a common platform to evaluate the strategic and financial impact of specific bids—at the country/product level or at the portfolio level—and share previous bidding experiences. We then developed a training program to bring the country teams up to speed on tender strategy and the tendering model.
Result: The platform has now been adopted by all country organizations at the company, has reduced excessive revenue losses, and improved confidence in bid decisions.
SAF to be used in Singapore departing flights from 2026
In this article, Marakon’s Rod Davies shares his thoughts on Singapore’s commitment to mandate the use of Sustainable Aviation Fuel (SAF) for departing...